SLGL News and Press, Sol-Gel Technologies Ltd. From 01/07/20

Sol-Gel Technologies (SLGL) had announced that it achieved positive results from its two pivotal studies using Twyneo to treat patients with acne vulgaris. The company prides itself on its drug delivery technology, microencapsulation, which is able to deliver topical treatments for these p...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watc...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmoplantar kerat...

Shares of Sol-Gel Technologies (NASDAQ: SLGL) rose as much as 36.2% today after the company announced positive results for its acne treatment Twyneo in multiple phase 3 clinical trials. The drug candidate met all three primary endpoints at the 12-week mark across both studies, including the ...

Neovasc (NASDAQ: NVCN ) +121%   files U.S. application for Reducer. More news on: Neovasc Inc., FuelCell Energy, Inc., Sol-Gel Technologies Ltd., Stocks on the move, Read more ...

Gainers: Savara (NASDAQ: SVRA )  +98% . More news on: Savara Inc., NIO Limited, Sol-Gel Technologies Ltd., Stocks on the move, Read more ...

Sol-Gel Technologies (NASDAQ: SLGL ) +160%  on Twyneo successful in acne studies. More news on: Sol-Gel Technologies Ltd., Savara Inc., NIO Limited, Stocks on the move, Read more ...

Ultra-thinly traded micro cap Sol-Gel Technologies (NASDAQ: SLGL ) rockets  148%  premarket, albeit on turnover of only 43K shares, in response to positive results from two Phase 3 clinical trials, SGT-65-04 and SGT-65-05 , evaluating topical cream Twyneo (microencapsulated tr...

All co-primary endpoints achieved in both Phase 3 clinical trials Twyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over time Additional data to be shared during the January 8 th investor conference call and webcast NESS...